Chinook delays topline kidney condition data; Eluminex ropes in $40M+ in a Series B
Chinook’s readout of its Phase III ALIGN trial of atrasentan, a potential treatment for chronic kidney diseases, could be delayed by about three months, the company said in an SEC filing. The trial is looking at atrasentan in patients with immunoglobulin A nephropathy (IgAN), a condition that can cause kidney disease.
The company said the FDA recommended that it add 12 weeks to an interim analysis of patients’ urine protein levels or proteinuria. That would push back the proteinuria data to the fourth quarter of this year. The company said it’s planning to meet with the agency to discuss the recommendation. — Katherine Lewin
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.